Keyphrases
Non-alcoholic Fatty Liver Disease (NAFLD)
100%
Crohn's Disease
50%
Proton Density Fat Fraction
19%
Inflammatory Bowel Disease
17%
Hepatic Steatosis
14%
Steatosis Index
12%
Internal Validation
12%
Dallas
12%
Risk Factors
12%
Endoscopy
12%
Independent Risk Factors
12%
Magnetic Resonance
11%
Low LDL Cholesterol
11%
Clinical Prediction Tool
11%
Liver Abnormality
11%
ASGE Guidelines
11%
Choledocholithiasis Risk
11%
Fraction Mapping
11%
Gastrointestinal Cancer
11%
Fibroblast Growth Factor 19 (FGF19)
11%
Shared Pathway
11%
Cost-effectiveness
11%
Endoscopic Retrograde Cholangiopancreatography
11%
Active Crohn's Disease
11%
Thiopurines
11%
Hepatotoxicity
11%
Total Neoadjuvant Therapy
11%
Short-course Radiotherapy
11%
Choledocholithiasis
11%
Bile Acid Diarrhea
11%
Locally Advanced Rectal Cancer
11%
Vertebral Body
11%
T2-weighted Magnetic Resonance Imaging
11%
Visceral Fat
11%
Quality-adjusted Life Years
9%
Irritable Bowel Syndrome
9%
Confidence Interval
8%
Long-course Chemoradiotherapy
8%
Diagnostic Test Performance
8%
Liver
7%
Bile Acids
7%
Quality of Care
6%
Care Pathway
6%
Transanal Total Mesorectal Excision (taTME)
6%
Body Mass Index
5%
Unique Mechanism
5%
Cost-effective Care
5%
Sensitivity Specificity
5%
Acid Production
5%
High-risk Criterion
5%
Medicine and Dentistry
Nonalcoholic Fatty Liver
77%
Crohn's Disease
26%
Non-Alcoholic Fatty Liver Disease
18%
Prevalence
17%
Patient with Crohn's Disease
13%
Health Care Cost
12%
Steatosis
12%
Endoscopy
12%
Proton Nuclear Magnetic Resonance
12%
Inflammatory Bowel Disease
12%
Cross Sectional Study
11%
Endoscopic Retrograde Cholangiopancreatography
11%
Common Bile Duct Stone
11%
Neoadjuvant Therapy
11%
Radiation Therapy
11%
Cost-Effectiveness Analysis
11%
Rectum Cancer
11%
Patient with Inflammatory Bowel Disease
11%
Gastrointestinal Cancer
11%
Bile Acid
11%
Diarrhea
11%
Population
10%
Quality Adjusted Life Year
9%
Chemoradiotherapy
8%
Fatty Liver
8%
Diagnostic Test
8%
Care Pathway
7%
Fibroblast Growth Factor 19
7%
Liver Disease
6%
Total Mesorectal Excision
6%
Irritable Bowel Syndrome
6%
Cholangiography
5%
Multivariate Analysis
5%
